1. Background {#sec1}
=============

Metabolic syndrome (MetS) is a set of closely associated cardiometabolic risks \[[@B1]\], like obesity, dyslipidemia, hypertension, and hyperglycemia and is seen as a powerful indicator of diabetes and cardiovascular disease (CVD) \[[@B2], [@B3]\]. The prevalence of metabolic syndrome continues to be on the rise; this is in part as a result of rapid urbanization with the related variations in nutrition and physical activity \[[@B4]\]. Worldwide the prevalence of metabolic syndrome has been reported as being between 10% and 84% \[[@B5]\]. In Africa, prevalence of 2.1% to 34.7% has been reported in several studies from around the continent \[[@B6], [@B7]\]. In Ghana, a prevalence of metabolic syndrome between 6% and 21.2% has been reported \[[@B8]\] using different criteria.

Haemoglobin A1c (HbA1c), a result of nonenzymatic glycosylation of the *β*-chain of haemoglobin, is made in proportion to the rise in blood glucose levels. It has been considered a preferable tool since HbA1c assay has superior technical advantages compared to the estimation of plasma glucose; it can be measured in the nonfasted state and has greater reproducibility than fasting glucose \[[@B9], [@B10]\]. HbA1c is a set-up marker of long haul glycemic control in individuals with diabetes mellitus (DM), and increased HbA1c levels are linked with an increased risk for later microvascular and macrovascular illness \[[@B11]\].

The fasting plasma glucose (FPG) cut-off figure for MetS may differ among various populaces. There are numerous reports recommending that HbA1c is superior to FPG in forecasting cardiometabolic risk even in nondiabetic individuals \[[@B12]--[@B14]\], with many others proposing that HbA1c may be an essential marker for MetS, but it stays a controversy \[[@B15]--[@B17]\]. However, HbA1c may be influenced by various haematologic, genetic, and disease-related factors \[[@B18]\]. The most important factors globally affecting HbA1c levels are some anaemias, haemoglobinopathies, and disorders linked with increased red blood cell turnover like malaria \[[@B9], [@B19]\].

A 1% rise in HbA1c raises the risk of CVD by 18% and positive relation between CVD and HbA1c has been shown in nondiabetic individuals even within normal values of HbA1c \[[@B20]\]. Many population-based studies from Western nations have investigated the link between HbA1c and the risk of CVDs (MetS) among nondiabetics \[[@B14], [@B21], [@B22]\], while only a few studies were from Africa and for that matter Ghana has examined this issue. Moreover, there is scarce evidence about whether or not adding HbA1c to other possible risk factors improves the ability to predict the Metabolic syndrome.

Previous studies have related HbA1c to glucose and weighed the option of replacing glucose with HbA1c for the criterion or adding HbA1c as an extra criterion for diabetes \[[@B17], [@B23]--[@B26]\]. However, data on the use of HbA1c as an indicator of MetS particularly in nondiabetic people are scanty and inconclusive, with some studies supporting the possible use of HbA1c as a marker for MetS, while other studies show divergence \[[@B15], [@B24], [@B27], [@B28]\]. While some studies have observed the importance of haemoglobin A1c in MetS, few have studied it in individuals with normal glucose levels. The aim of the study was to explore the comparative abilities of HbA1c and FPG in predicting metabolic syndrome in apparently healthy normoglycemic adults within the Tamale metropolis of Ghana.

2. Methods {#sec2}
==========

2.1. Subjects {#sec2.1}
-------------

This study was a cross-sectional study conducted among apparently healthy adults (18 years and above) with no history of diabetes within the Tamale metropolis from September, 2017, to January, 2018.

### 2.1.1. Exclusion Criteria {#sec2.1.1}

Diabetics, hypertensives, persons treating diabetes or hypertension, persons with a fasting blood glucose \>7.0 mmol/l or HbA1c ≥6.5% at the time of the study, pregnant women, persons showing signs of any acute illnesses, and persons with other chronic diseases were excluded from this study.

### 2.1.2. Sample Size {#sec2.1.2}

The minimum sample size for the study was calculated to be 105 adults, based on the assumption that 7.4% of the normal adult populations have metabolic syndrome \[[@B29]\], with an expected difference of 5% between the sample and the general population and a type I error (*α*) of 0.05.

This study was limited to only apparently healthy adults who answered at least 75% of the questions in the questionnaire and did not have an FPG of \>7.0 mmol/l or an HbA1c of \>6.5; hence, the sample size was recalculated to adjust for any possible loss of respondents. Assuming a response rate of 90%, the sample size was recalculated to be approximately 117. One hundred and twenty (120) participants were therefore targeted for this study.

2.2. Data Collection {#sec2.2}
--------------------

### 2.2.1. Sociodemographic and Anthropometric Data {#sec2.2.1}

A self-designed semistructured questionnaire was administered to consented study participants for sociodemographic data. Weight to the nearest 0.1 kg was measured using a digital flat floor weighing scale (with weighing capacity of 250 kg) manufactured by SECA (Hamburg, Germany) and height to the nearest 1 cm was measured using a portable microtoise (measuring range: 0 cm to 220 cm) manufactured by SECA. Waist circumference (to the nearest centimetre) was measured with a Gulick II spring-loaded measuring tape (Gay Mill, WI) midway between the inferior angle of the ribs and the suprailiac crest. Hip circumference was measured as the maximal circumference over the buttocks in centimetre.

### 2.2.2. Blood Pressure {#sec2.2.2}

Blood pressure was measured in sitting position, with a sphygmomanometer cuff and a stethoscope. Measurements were taken from the left brachial artery after subjects had been sitting for at least five (5) minutes in accordance with the recommendation of the American Heart Association \[[@B30]\]. Triplicate measurements were taken with a five (5) minute rest interval between measurements and the mean value was recorded to the nearest 2.0 mmHg.

### 2.2.3. Sample Collection, Preparation, and Analysis {#sec2.2.3}

Ten milliliters (10 ml) of venous blood sample was collected under strict aseptic conditions from each participant in the morning between 07.00 and 09.00 GMT into fluoride oxalate tube, Serum Separator Tubes (SST), and ethylenediaminetetraacetic acid (EDTA) anticoagulated tube (Becton Dickinson, Rutherford, NJ), after an overnight (8-12 hours) fast. Samples in the fluoride oxalate tubes were centrifuged and plasma was used for glucose measurement (within 2 hours after sample collection) using the Glucose oxidase peroxidase (GOD-POD) method whilst samples in the SST were centrifuged at 3000 g for 5 minutes and the serum was aliquoted and stored in cryovials at a temperature of -80°C until time for biochemical assays. Lipid profile and fasting blood glucose levels were determined using the Mindray BS-240 Chemistry Analyser (Mindray, China); MedSource Diagnostics reagents were used in all of these assays. The anticoagulated (EDTA) blood was used for the HbA1c Assay using the MedSource Diagnostics reagents for Glycosylated Haemoglobin (A1-fast fraction) test kit which uses the Cation Exchange Method. For the within run (intra-assay) precision, a % CV was 2.7 in normal HbA1c samples and 1.7 in elevated HbA1c samples was quoted while for the run to run (Inter run) precision a % CV was 4.1 for normal samples and 4.6 for elevated samples were quoted by manufacturers. Samples from subjects with haemoglobinopathies or decreased erythrocytes survival times may show incorrect results. This method is not listed in the 2019 National Glycohemoglobin Standardization Program (NSGP) method traceability list.

2.3. Definitions of Metabolic Syndrome {#sec2.3}
--------------------------------------

### 2.3.1. Metabolic Syndrome: Harmonised Criteria by the Joint Interim Statement (JIS) {#sec2.3.1}

Metabolic syndrome was defined to include individuals with any three or more of the following five components: (1) abdominal obesity (waist circumference, Male ≥94, Female ≥80), (2) high triglyceride ≥ 1.7 mmol/L (150 mg/dl), (3) low HDL-C: Male\< 1.0, Female \<1.3 mmol/L, (4) High BP (systolic BP ≥ 130 mm Hg or diastolic BP ≥ 85 mm Hg or treatment of hypertension), and (5) high fasting glucose ≥ 5.6 mmol/l \[[@B31]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

All analyses were performed using MedCalc® version 10.2.0.0 (www.medcalc.be) for windows and GraphPad version 6.0, San Diego, California, USA. Unpaired T-test was used to compare continuous variables. Association between variables was assessed with linear regression analysis. Receiver Operator Characteristics (ROC) was used to compare the relative abilities of various parameters to predict MetS and other cardiovascular risk factors. In all statistical analyses, a p value of \<0.05 was considered significant.

3. Results {#sec3}
==========

3.1. General Characteristics of Studied Population {#sec3.1}
--------------------------------------------------

A total of 160 complete questionnaires were analysed, of which 68 (42.5%) were males and 92 (57.5%) females. Subjects with metabolic syndrome were significantly older than subjects without the metabolic syndrome. The average HbA1c and FPG of the study population were 4.8±1.2% and 4.95±0.92 mmol/L, respectively. These parameters were higher in respondents with MetS; however, only the difference in FPG was statistically (p\<0.001) significant as shown in [Table 1](#tab1){ref-type="table"}

3.2. Biochemical Parameters of Studied Population Stratified by Gender {#sec3.2}
----------------------------------------------------------------------

[Table 2](#tab2){ref-type="table"} summarises the biochemical parameters of the studied population stratified by gender. Female respondents were older (43.8±14.3 years) than the male (41.4±14.8 years) but this was not statistically significant. Female respondents with MetS however were significantly older than those without MetS. In females only, FPG was significantly higher in MetS as shown in [Table 2](#tab2){ref-type="table"}.

3.3. Biochemical Characteristics according to MetS Score {#sec3.3}
--------------------------------------------------------

[Table 3](#tab3){ref-type="table"} shows the anthropometric and biochemical variations in MetS scores. Generally, FPG significantly showed an increasing trend while moving from a score of 0 to a score of 3 or more.

3.4. Association between HbA1c, FPG, Lipid Parameters, and MetS Score {#sec3.4}
---------------------------------------------------------------------

A linear regression between HbA1c, FPG, and selected cardiometabolic risk is shown in [Table 4](#tab4){ref-type="table"}. HbA1c had significant positive association with triglyceride and VLDL-c. A percentage increase in HbA1c results in a 0.12 mmol (r^2^=0.03, p\<0.05) increase in Triglyceride and 0.05 mmol (r^2^=0.03, p\<0.05) increase in VLDL-c. FPG however showed significant positive association with SBP, DBP, total cholesterol, triglyceride, and VLDL-c. A 1 mmol/L increase in FPG is associated with an increase in 0.33 mmol/L (r^2^=0.05, p\<0.01) of total cholesterol, 0.21 mmol/L (r^2^=0.05, p\<0.01) of triglyceride, and a 0.10 mmol/L (r^2^=0.05, p\<0.01) increase in VLDL-c.

3.5. Receiver Operator Characteristics (ROC) for HbA1c and FPG in the Studied Population {#sec3.5}
----------------------------------------------------------------------------------------

The ROC curves and the Area under Curve (AUC) between HbA1c and FPG against MetS and its individual components are shown in [Figure 1](#fig1){ref-type="fig"} and [Table 5](#tab5){ref-type="table"}. FPG had the largest AUC for all variables assessed, that is, MetS, 2 or more nonglycemic components, abdominal obesity, elevated BP, elevated triglyceride, and reduced HDL-c ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

The role of impaired glucose metabolism in the pathogenesis of MetS and its adverse effects on CVDs and diabetes outcomes has been well documented \[[@B32], [@B33]\]. Hyperglycemia is known to compound the problem in MetS through the formation of advanced glycation end products \[[@B34]\].

Fasting plasma glucose and haemoglobin A1c measurements have been used over the years in the diagnosis of impaired glucose metabolism. However, proper consensus has not been reached about which there is a better diagnostic tool, associates better with cardiometabolic risk, and can be used as a predictive tool for MetS, especially among normoglycemic individuals. Some studies have shown that haemoglobin A1c associates better with cardiometabolic risk \[[@B16], [@B24], [@B35]\].

This study however found that haemoglobin A1c does not associate better with cardiometabolic risk and has no superior ability in predicting the presence of MetS among a normoglycemic northern Ghanaian population. Succurro and Marini \[[@B23]\] pointed out that the classification of MetS using a HbA1c criterion instead of glucose performed worse in detecting some subjects who still had an unfavourable cardiometabolic risk profile. Several other studies have reported similar findings, especially among a normoglycemic population \[[@B36]\].

The adverse effects of impaired glucose metabolism and diabetes are as a result of the elevated glucose levels and not elevated levels of haemoglobin A1c which is only reflective of a chronic exposure to high plasma glucose concentration \[[@B37]\]. There is evidence that each of the glycemic measures used to identify prediabetes represents a different domain of glucose metabolism. While FPG reflects basal dysglycemia, HbA1c reflects chronic exposure to basal and postprandial hyperglycemia \[[@B37]\]. A nonlinear relationship between glycemia and the haemoglobin A1c in normoglycemic populations has been observed in a number of studies which have shown that glycemia may be a less important determinant of hemoglobin glycation and that other factors operate to produce consistent changes in HbA1c. Potential explanations for this variation in hemoglobin glycation at or near normal glucose levels have focused on interindividual variation in red cell turnover \[[@B38]\], differences between the intraerythrocyte and extraerythrocyte environment \[[@B39]\], and genetic variation in hemoglobin glycation \[[@B40]\]. This means that, in a normoglycemic population, estimation of glucose levels will correlate better with adverse cardiometabolic outcomes than haemoglobin A1c as shown in the present study.

In this study, though there was no estimation of haemoglobin glycation index (HGI) and data on HGI among African populations that remain sparse, some studies in developed countries have revealed a lower glycation index among African Americans and Caucasians compared with Hispanics \[[@B41]\]. This means that, even at elevated glucose levels, formation of haemoglobin A1c among the population in the present study may have been slow and hence haemoglobin A1c did not reflect the glycemia. Hence, the subsequent absence of association between glycation and the cardiometabolic risk factors and its inability to properly predict MetS and its components compared to Fasting Blood Glucose.

Various combinations of haemoglobin variants C and S have been reported to falsely lower the values of HbA1c. The reported higher frequencies of these variants especially haemoglobin C among sub-Saharan Africans \[[@B42], [@B43]\] could be linked to the nonperformance of HbA1c in this study, and therefore the impact of haemoglobinopathies in this current study cannot be underestimated especially among a study population of predominantly Northern descent where the prevalence of the haemoglobin C has been shown to be appreciable \[[@B44]\].

5. Conclusion {#sec5}
=============

This study demonstrates that, in a normoglycemic population, FPG associates better with Metabolic syndrome and other cardiometabolic risks than HbA1c and that fasting blood glucose estimation is shown to be the best predictor of MetS and its components among an apparently normoglycemic population.

5.1. Limitations {#sec5.1}
----------------

The estimation of haemoglobin A1c in this study was limited to only one method (Medsource Ozone Biomedicals Pvt., Ltd.) which is not listed on the 2019 NSGP certified methods list.
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MetS:

:   Metabolic syndrome

HbA1c:

:   Haemoglobin A1c

FPG:

:   Fasting blood glucose

CVD:

:   Cardiovascular disease

DM:

:   Diabetes mellitus

SST:

:   Serum separator tube

EDTA:

:   Ethylene diamine tetraacetic acid

HDL-c:

:   High density lipoprotein cholesterol

LDL-c:

:   Low density lipoprotein cholesterol

VLDL-c:

:   Very low-density lipoprotein cholesterol

HGI:

:   Haemoglobin glycation index.
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###### 

Biochemical parameters of studied population stratified by MetS.

  Variables      Total       No MetS     MetS        P value
  -------------- ----------- ----------- ----------- ---------
  Age (years)    42.8±14.5   41.6±14.6   48.2±12.9   0.030
  HbA1c (%)      4.8±1.2     4.8±1.2     5.2±1.3     0.080
  FPG (mmol/L)   5.0±0.9     4.8±0.9     5.8±0.7     \<0.001

HbA1c: Haemoglobin A1c and FPG: Fasting Blood Glucose. Data are presented as mean ± SD and compared using T-test.

###### 

Biochemical parameters of studied population stratified by gender.

  Variables      Male        Female                                            
  -------------- ----------- ----------- ----------- ----------- ------------- -----------
  Age (years)    41.4±14.8   41.8±15.2   38.6±10.9   43.8±14.3   41.5±14.2‡‡   52.0±11.8
  HbA1c (%)      4.8±1.3     4.8±1.3     5.1±1.1     4.9±1.2     4.7±1.1       5.3±1.3
  FPG (mmol/L)   5.0±0.9     5.0±0.9     5.6±0.7     4.9±1.0     4.6±0.9‡‡‡    5.8±0.7

HbA1c: Haemoglobin A1c and FPG: Fasting Blood Glucose. Data are presented as mean ± SD and compared using T-test. ‡Comparing females with MetS with females without MetS. ‡Comparison is significant at the 0.05 level, ‡‡Comparison is significant at the 0.01 level, and ‡‡‡Comparison is significant at the 0.001 level.

###### 

Biochemical characteristics stratified by MetS component score.

  Variable       MetS score                                               
  -------------- ------------ ----------- ----------- ----------- ------- ---------
  Age (years)    34.6±11.8    42.4±14.2   48.3±15.0   48.2±12.9   8.66    \<0.001
  HbA1c (%)      4.8±1.1      4.8±1.3     4.6±1.2     5.2±1.3     1.24    0.297
  FPG (mmol/L)   4.43±0.78    4.9±0.9     5.0±0.9     5.8±0.7     14.46   \<0.001

HbA1c: Haemoglobin A1c and FPG: Fasting Blood Glucose. Data are presented as mean ± SD and compared using One-way ANOVA.

###### 

Linear regression analysis between HbA1c, FPG, and selected indicators of cardiometabolic risk factors.

  Variable                     HbA1c     FPG                
  ---------------------------- --------- ------ ----------- ------
  SBP (mmHg)                   0.58      0.00   4.10*∗∗*    0.06
  DBP (mmHg)                   -0.26     0.00   2.17*∗*     0.03
  HbA1dc-Dcct (%)              \-        \-     0.12        0.01
  FPG (mmol/L)                 0.07      0.01   \-          \-
  Total cholesterol (mmol/L)   0.07      0.00   0.33*∗∗*    0.05
  Triglyceride (mmol/L)        0.12*∗*   0.03   0.21*∗∗*    0.05
  HDL-c (mmol/L)               0.00      0.00   0.22        0.04
  LDL-c (mmol/L)               0.02      0.00   0.01        0.00
  VLDL-c (mmol/L)              0.05*∗*   0.03   0.10*∗∗*    0.05
  MetS score                   0.06      0.00   0.56*∗∗∗*   0.20

*∗*Regression is significant at the 0.05 level, *∗∗*regression is significant at the 0.01 level, and *∗∗∗*regression is significant at the 0.001 level.

###### 

AUC for HbA1c and FPG in predicting MetS and its components.

  Variable                         HbA1c              FPG
  -------------------------------- ------------------ ------------------
  MetS                             0.62(0.54-0.69)    0.84(0.78- 0.89)
  2 or more nonglycemic criteria   0.53(0.45- 0.61)   0.62(0.54- 0.69)
  Abdominal obesity                0.53(0.45-0.61)    0.61(0.53- 0.69)
  Elevated BP                      0.54(0.46- 0.62)   0.64(0.56- 0.71)
  Elevated triglyceride            0.62(0.54- 0.69)   0.66(0.58- 0.73)
  Reduced HDL-c                    0.58(0.50- 0.66)   0.73(0.65- 0.80)

Results are expressed as Area under Curve (confidence interval).
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